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Background: Prisoners have extremely high rates of smoking with rates 3–4 times higher than the general
community. Many prisoners have used heroin. The aims of this study were to investigate the impact of heroin use
on smoking cessation and the social determinants of health among prisoners.
Methods: Secondary analysis of data from a randomised controlled trial of a multi-component smoking cessation
intervention involving 425 Australian male prisoners. Inmates who, prior to imprisonment, used heroin regularly
were compared to those who did not use heroin regularly. Self-reported smoking status was validated at baseline
and each follow-up by measuring carbon monoxide levels. Readings exceeding 10 ppm were defined as indicating
current smoking.
Results: Over half (56.5%) of the participants had ever used heroin while 37.7% regularly (daily or almost daily) used
heroin in the year prior to entering prison. Prisoners who regularly used heroin had significantly worse social
determinants of health and smoking behaviours, including lower educational attainment, more frequent incarceration
and earlier initiation into smoking. Prisoners who regularly used heroin also used and injected other drugs significantly
more frequently. At 12-month follow-up, the smoking cessation of prisoners who had regularly used heroin was also
significantly lower than prisoners who did not regularly use heroin, a finding confirmed by logistic regression.
Conclusions: Regular heroin use prior to imprisonment is an important risk factor for unsuccessful attempts to quit
smoking among prisoners and is also associated with worse social determinants of health, higher drug use, and worse
smoking behaviours. More effective and earlier smoking cessation interventions are required for particularly
disadvantaged groups.
Trial registration: This trial is registered with the Australian New Zealand Clinical Trials Registry 12606000229572.
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Smoking cessation efforts among the Australian commu-
nity have led to a decline in smoking prevalence from a
high of 72% of men and 26% of women in 1945 to a
current regular smoking rate of 22% in men and 18% in
women [1,2]. However, this trend is not seen in socially
disadvantaged populations, such as prisoners, those with
a mental illness, and illicit drug users [3-5]. The 2009* Correspondence: d.indig@unsw.edu.au
†Equal contributors
1Justice & Forensic Mental Health Network, Centre for Health Research in
Criminal Justice, Suite 302, Level 2, 152 Bunnerong Road, Pagewood, NSW
2035, Australia
2School of Public Health and Community Medicine, University of New South
Wales, Sydney, NSW 2052, Australia
Full list of author information is available at the end of the article
© 2013 Indig et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orNew South Wales (NSW) Inmate Health Survey, which
randomly sampled 996 prisoners in custody, reported
75% of male and 80% of female prisoners were current
smokers [6]. Among those entering prisons across
Australia, the rate of smoking was higher (85%), and high-
est among prisoners reporting a history of injecting drug
use (93%) [7]. However, a substantial proportion of pris-
oners report wanting to stop smoking [3,6,8,9].
The 2012 World Drug Report estimates that between
0.6% and 0.8% of the world’s population aged between
15 and 64 years used opioid drugs with heroin the most
widely used opioid [10]. In Australia in 2010, among
those aged 14 and over 1.4% reported using heroin while
0.2% used heroin in the previous year [1]. The rate of
heroin use was significantly higher among prisoners intd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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using heroin on a daily/almost daily basis in the past
year and 15% having ever used heroin in prison [6].
Among Australian prison entrants who participated in a
National Prisoner Health Census in 2009, 19% of pris-
oners reported using heroin in the year before entering
prison [11]. Heroin use among prisoners and the
broader Australian community has decreased in the past
decade following the heroin shortage of 2000, but rates
are still high [12,13].
Most people who currently use heroin or are on
opioid substitution treatment (such as methadone or
buprenorphine) also smoke cigarettes [9]. A recent
Australian study found the prevalence of smoking was
84% among methadone users [14] and another study of
heroin users reported 97% were smokers [15]. A qualita-
tive study [16] asked drug users currently in treatment
about the relationship between their smoking, methadone
and drug use. The participants reported that drug use and
smoking were complementary in managing side effects of
both substances and withdrawal symptoms [16]. Smoking
cessation rates among opioid-dependent people are lower
than among the general population, however many still
want to quit [17,18].
Few studies have investigated how heroin use may
affect smoking cessation intervention outcomes [19].
The aims of this paper were to assess the impact of
regular heroin use in the year before entering prison on
the social determinants of health, smoking behaviours
(such as age of initiation and amount smoked per day)
and success of quitting smoking among prisoners. As a
high proportion of prisoners are current smokers and
have used heroin, it is important that we improve our
understanding of the relationship between the two in
order to develop more effective smoking cessation inter-




This study involved a secondary analysis of data from a
randomised controlled trial of a multi-component smok-
ing cessation intervention among prisoners. This analysis
compared prisoners who, prior to imprisonment, were
regular (daily or almost daily use) heroin users with pris-
oners who were not regular heroin users (i.e. used her-
oin less than regularly). The trial recruited 425 male
prisoners who received 13 weeks of nicotine replace-
ment therapy, two sessions of brief cognitive behavioural
therapy, had access to a Quitline, and were provided
with smoking cessation support materials (e.g. a booklet
designed by the investigators to assist with coping with
prison stressors and a QUIT calendar). Participants were
randomised to receive either active nortriptyline or placeboto assess the impact of the antidepressant on assisting
participants to quit smoking. Ethics committees from the
University of New South Wales, Justice Health NSW,
Corrective Services NSW, the Aboriginal Health and
Medical Research Council and Queensland Corrective
Services approved the study. A full description of the
methods, study intervention and results of the randomised
controlled trial are reported elsewhere [20].
Participants and recruitment
Recruitment took place in 17 prisons in NSW (N = 407)
and one prison in Queensland (N = 18) among prisoners
who were current smokers and who indicated they
wished to quit smoking. Between August 2006 and
September 2009, 1,751 prisoners expressed interest in
participating in the study and were assessed by a re-
search nurse and doctor regarding the selection criteria.
The majority (N = 1,315) were considered ineligible for
the following reasons: having less than six months left
on their sentence (35%), being on psychiatric medication
or having a history of psychiatric illness (40%) or a his-
tory of cardiac disease (5%). Female prisoners were con-
sidered ineligible, as they only constitute 7% of the NSW
prisoner population and generally have shorter sentences
[21]. All participants provided written informed consent
and were paid $10 for each interview completed. Partici-
pants were followed up both in prison and the community
at 3, 6 and 12 months to assess the point prevalence, con-
tinuous abstinence and smoking reduction. Follow-up
rates were 90% at 3 months, 87% at 6 months, and 80% at
12 months, with no difference in follow-up rates for par-
ticipants in the active nortriptyline and placebo groups.
There was also no significant difference among partici-
pants who were regular or not regular heroin users regard-
ing their assignment to treatment or placebo group, or
with regard to their rate of follow-up.
Questionnaires and measures
Participants were administered a baseline questionnaire
face-to-face by research nurses. The baseline ques-
tionnaire included questions on socio-demographics,
offending history, smoking behaviours, smoking history,
physical health, mental health and alcohol and other drug
use. The follow-up questionnaires included most of the
same measures in the baseline. The questions related to
use of heroin (and all drugs) including if they ‘ever used’ or
‘used regularly (daily/almost daily) in the 12 months before
prison’. Smoking behaviours were measured using ques-
tions related to the number of cigarettes smoked before
prison, years of regular smoking and prior quit attempts.
Nicotine dependence was assessed using the Fagerström
Test for Nicotine Dependence [22].
The primary smoking cessation outcome measures
were point prevalence, continuous abstinence and 50%
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baseline) measured at 12 months. These outcome mea-
sures were determined on an intention-to-treat basis [23]:
if a participant missed a particular follow-up they were
regarded as a smoker at that time period. Self-reported
smoking status was validated at baseline and each follow-
up by measuring carbon monoxide levels and readings
exceeding 10 ppm were classified as a smoker [24].
Statistical analysis
Questionnaires were double-key entered into an elec-
tronic database and the data were cleaned for potential
errors. Statistical analysis was performed using SAS
version 9.2 [25]. Descriptive and inferential statistics
(including chi-square and t-tests) were used to determine
any statistically significant differences (p ≤ 0.05) across a
range of characteristics for inmates who regularly used
heroin compared with those who had not regularly used
heroin in the year before prison. For the smoking cessa-
tion outcome variables, intention-to-treat analyses [23]
were utilised with missing data classified as either continu-
ing smoking or not reducing the amount smoked by 50%.
This included chi-square analysis and logistic regression
for the major outcome variables of point prevalence and
continuous abstinence at 12 months. There were no sig-
nificant differences in the follow-up rates for regular ver-
sus non-regular heroin users. In the logistic regression
models, potential confounders were controlled for includ-
ing any socio-demographics and other drug use character-
istics which were significant.
Results
Socio-demographics, drug use and offending history by
regular heroin users
Among the 425 male participants, over half (56.5%) had
ever used heroin and 37.7% regularly (daily/almost daily)
used heroin in the 12 months before entering prison.
Prisoners who had regularly used heroin before prison
were significantly younger than those who had not used
heroin regularly (Table 1). Other socio-demographic char-
acteristics which were significantly worse for prisoners
who were regular heroin users included: institutionalisation
as a child, leaving school with no qualification and at a
younger age and being homeless prior to entering prison.
Prisoners with a history of regular heroin use in the
year before entering prison were significantly more likely
to have ever used all other types of drugs, as well as
regularly (daily or almost daily) using all other types of
drugs prior to prison than prisoners who were not regu-
lar heroin users prior to entering prison. Similarly, pris-
oners who were regular heroin users prior to entering
prison were significantly more likely to have been previ-
ously incarcerated and had twice as many adult prison
terms than prisoners who were not regular heroin users.Smoking history, cessation behaviours and outcomes by
regular heroin users
The mean ages for first smoking tobacco and for smok-
ing tobacco on a daily basis were significantly lower for
prisoners who were regular heroin users compared to
those who were not regular heroin users (Table 2). There
were no significant differences between participants who
regularly used heroin and those who did not with regard
to the quantity of tobacco smoked or nicotine depend-
ence score. Participants who had regularly used heroin
were significantly less likely to have attempted unsuccess-
fully to quit smoking in the past year, but there were no
significant differences in the number of quit attempts.
The outcomes of the smoking cessation intervention
identified lower rates of quitting smoking for point
prevalence (5.0% vs. 18.5%, P < 0.01) and continuous ab-
stinence (3.8% vs.16.6%, P < 0.01) at 12-month follow-up
for participants who were regular heroin users prior to
prison. There were no significant differences between
participants who were regular heroin users and those
who were not with regard to having taken the study
medication (NOR), nor with the outcome of reducing
the quantity of tobacco smoked by 50% at 12 months.
Predictors of smoking abstinence
Table 3 identifies potential predictors of smoking abstin-
ence (both point prevalence and continuous abstinence)
at 12 months, including socio-demographic, drug use
and smoking behaviours which were significantly differ-
ent between participants who, before entering prison,
were regular heroin users and those who were not. The
crude odds ratio for both models identified the following
predictors of successfully quitting smoking at 12 months:
being in prison for the first time, being in prison for five
or more years, not being a regular heroin user and not
being a regular user of other drugs (excluding heroin).
When these predictors which were significant in the
crude model were incorporated into the logistic regres-
sion model, not being a regular heroin user was the pri-
mary predictor for both point prevalence (OR = 3.81,
95% CI: 1.65-8.78) and continuous abstinence (OR = 4.29,
95% CI: 1.69-10.90).
Discussion
This paper concludes that heroin use in the year before
entering prison is associated with a reduced likelihood
of stopping smoking at 12 months following a multi-
component smoking cessation intervention. This finding
remained significant after controlling for regular use of
drugs other than heroin, which strengthens the specifi-
city of this association. Though there are a number of
studies identifying the importance of implementing
smoking cessation interventions among people in opioid
treatment programs [5,26,27], no studies were found which
Table 1 Socio-demographics, drug use and offending history by regular use of heroin in year before prison
Not regularly used heroin %
(N = 265)







< 25 years 25.3 19.4 23.1
25-29 years 17.4 24.4 20.0 P < 0.01
30-39 years 23.4 37.5 28.7
40+ years 34.0 18.9 28.2
Mean age 34.4 32.0 33.5 P < 0.02
(+SD; Range) (11.2; 18–65) (8.0; 19–54) (10.2; 18–65)
Aboriginal origin 14.3 16.3 15.1 NS
Born in Australia 74.8 75.0 74.9 NS
Left school no qualification 39.3 50.6 43.5 P < 0.03
Mean age left school 15.5 14.6 15.1 P < 0.01
(+SD; Range) (1.7; 12–26) (2.3; 0–19) (2.0; 0–26)
Institutionalised as a child (juvenile detention
and/or placed in care)
31.3 48.8 37.9 P < 0.01
Homeless prior to prison 4.5 11.3 7.1 P < 0.01
Employed while in prison 79.3 60.0 72.0 P < 0.01
Ever use drugs by drug type
Cannabis 89.1 98.8 92.7 P < 0.01
Amphetamines 66.0 95.0 76.9 P < 0.01
Cocaine 44.2 81.9 58.4 P < 0.01
Heroin 30.1 100.0 56.5 P < 0.01
Other opiates 18.9 66.9 36.9 P < 0.01
Tranquilisers 22.6 66.9 39.3 P < 0.01
Any drugs (other than heroin) 92.1 100.0 38.6 P < 0.01
Any drugs 92.5 100.0 95.3 P < 0.01
Regularly (daily or almost daily) use drugs
prior to prison by drug type
Cannabis 52.8 73.1 60.5 P < 0.01
Amphetamines 41.9 60.0 48.7 P < 0.01
Cocaine 23.8 56.9 36.2 P < 0.01
Other opiates 3.0 37.5 16.0 P < 0.01
Tranquilisers 6.4 35.6 17.4 P < 0.01
Any drugs (other than heroin) 69.1 92.5 77.9 P < 0.01
Any drugs 69.4 100.0 80.9 P < 0.01
Offending history
Previously incarcerated 50.6 85.6 63.8 P < 0.01
Median number adult prison terms 2.0 4.0 2.0 P < 0.01
(+SD; Range) (2.7; 1–20) (2.8; 1–15) (2.9; 1–20)
Median years in prison at baseline 1.9 1.8 1.9 NS
(+SD; Range) (4.2; 0.02-27.1) (4.1; 0.03-23.2) (4.2; 0.02-27.1)
Median sentence length in years 3.9 3.1 3.6 NS
(+SD; Range) (13.4; 0.5-113.9) (15.4; 0.4-115.8) (14.2; 0.4-115.8)
Abbreviations: SD = standard deviation; NS = not significant.
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Table 2 Smoking history, cessation behaviours and outcomes by regular use of heroin in year before prison
Not regularly used heroin %
(N = 265)






Mean age first smoked tobacco 14.1 13.0 13.7 P < 0.02
(+SD; Range) (4.8; 5–39) (3.1; 5–22) (4.3; 5–39)
Mean age first smoked tobacco daily 16.0 14.6 15.5 P < 0.01
(+SD; Range) (4.6; 5–39) (3.2; 7–30) (4.2; 5–39)
Mean years smoked tobacco 20.3 19.0 19.8 NS
(+SD; Range) (11.2; 0–52) (8.4; 3–46) (10.2; 0–52)
Mean carbon monoxide reading 14.1 14.5 14.3 NS
(+SD; Range) (7.5; 1–43) (8.2; 3–59) (7.8; 1–59)
Mean cigarettes smoked per day 23.1 23.3 23.2 NS
(+SD; Range) (10.3; 3–75) (8.9; 5–60) (9.8; 3–75)
Smoke 20+ cigarettes per day 67.6 74.4 70.1 NS
High tobacco dependence (Fagerström 6+) 80.8 86.3 82.8 NS
Share a cell with a smoker 32.2 35.6 33.5 NS
Smoke White Ox (loose tobacco) 97.0 97.5 97.2 NS
Smoking cessation behaviours
Mean times tried to quit smoking 2.9 2.2 2.6 NS
(+SD; Range) (8.6; 0–128) (2.6; 0–20) (7.9; 0–128)
Quitting behaviours in past year
Given up more than one month 14.0 11.3 12.9 NS
Tried to give up unsuccessfully 64.2 53.8 60.2 P < 0.04
Lower tar or nicotine content 7.9 4.4 6.6 NS
Reduced amount tobacco smoked 50.2 43.8 47.8 NS
Quit on purpose for 24 hours 57.0 48.1 53.7 NS
Any type of quitting behaviour 76.2 68.8 73.4 NS
Smoking cessation intervention outcomes
Active NOR versus placebo NOR 49.4 46.9 48.5 NS
Quit smoking at 12 months: point prevalence 18.5 5.0 13.4 P < 0.01
Quit smoking at 12 months: continuous abstinence 16.6 3.8 11.2 P < 0.01
50% smoking reduction at 12 months 76.2 72.2 74.7 NS
Abbreviations: SD = standard deviation; NS = not significant; NOR = nortriptyline.
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an unsuccessful quit smoking attempt. As nearly half of
smokers die of a tobacco-related illness [28] and the annual
mortality rate for heroin-dependent people is a further 2%
[29], the combined risk factors of smoking and heroin
dependence have important public health implications.
The findings of this study suggest that future smoking
cessation interventions should consider identifying con-
current drug addictions (particularly heroin) and identify
strategies to deal with all drug problems at the same
time. There is a growing body of evidence supporting
multiple behaviour change interventions which can be
applied to addressing smoking cessation and drug use
[30,31]. A recent meta-analysis of the outcomes of smokingcessation interventions among participants in drug and
alcohol treatment identified that smoking cessation inter-
ventions were associated with a 25% increase in long-term
drug and alcohol abstinence [32], a finding supported by
other studies [33,34]. As many persons undergoing treat-
ment for heroin dependence in the community may later
enter prison [35], strong support to quit smoking should
be provided as a routine in all drug treatments for heroin
dependence.
Prisoners with a history of regular heroin use in the
year prior to entering prison had significantly poorer social
determinants of health such as poor educational attain-
ment, higher involvement in out-of-home care, and were
also more likely to be homeless. These determinants are
Table 3 Predictors (crude and adjusted odds ratios) of smoking abstinence at 12 months
Point prevalence Continuous abstinence
Crude Adjusted Crude Adjusted
Odds Ratio (95% CI) Odds ratio (95% CI) Odds Ratio (95% CI) Odds ratio (95% CI)
Active NOR versus placebo NOR 0.81 (0.46-1.42) 0.89 (0.49-1.62) 0.98 (0.54-1.77) 1.07 (0.57-2.00)
Age 35+ years 1.86 (1.06-3.25)† 1.46 (0.77-2.75) 1.64 (0.91-2.97) 1.36 (0.70-2.65)
Aboriginal origin 0.50 (0.19-1.31) 0.53 (0.19-1.48) 0.60 (0.23-1.56) 0.61 (0.22-1.72)
Left school no qualification 0.55 (0.31-1.01) - 0.70 (0.38-1.29) -
Institutionalised as a child 0.66 (0.36-1.21) - 0.60 (0.32-1.16) -
Homeless prior to prison 0.70 (0.21-2.39) - 0.82 (0.24-2.82) -
Employed while in prison 1.74 (0.87-3.48) - 1.89 (0.89-4.02) -
Tried to give up unsuccessfully 0.89 (0.51-1.57) - 0.75 (0.41-1.36) -
First time in prison 2.19 (1.25-3.84)† 1.47 (0.79-2.72) 2.52 (1.38-4.57)† 1.68 (0.88-3.20)
Incarcerated 5+ years at baseline 2.67 (1.44-4.96)† 2.30 (1.17-4.52)† 2.16 (1.11-4.20)† 1.88 (0.91-3.88)
Not regular drug use (excluding heroin) in year
prior to prison
2.37 (1.33-4.19)† 1.31 (0.65-2.62) 2.39 (1.30-4.39)† 1.33 (0.64-2.75)
Not regular heroin use in year prior to prison 4.31 (1.98-9.36)† 3.81 (1.65-8.78)† 5.11 (2.13-12.29)† 4.29 (1.69-10.90)†
Abbreviations: NOR = nortriptyline † P < 0.05.
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reduce the success rate for smoking cessation interventions
[36,37]. Further, participants who used heroin regularly
prior to prison also were significantly more likely to have
been previously incarcerated and had a median of twice as
many previous times in prison compared to those who had
not used heroin regularly. Increased involvement in the
criminal justice system is likely to exacerbate poverty,
homelessness and other social disadvantages which are as-
sociated with tobacco smoking [38].
Another key characteristic of prisoners who had regu-
larly used heroin in the year before entering prison is
that they started smoking at a younger age and reported
significantly more other drug use than prisoners who
did not report regular heroin use. It is well documented
that drug and alcohol treatment services often fail to ad-
dress underlying tobacco dependence [39-41]. Some rea-
sons for this include inadequate staff knowledge and
training for providing smoking cessation interventions,
high smoking prevalence rates among staff, and ambiva-
lent attitudes and beliefs related to tobacco among staff
[41]. These barriers to providing smoking cessation among
people with drug and alcohol problems may be addressed
through providing enhanced staff education and training in
smoking cessation, supporting staff to quit smoking and
creating a smoke-free environment for drug and alcohol
treatment services [42]. The magnitude of the barriers to
treatment provision and uptake for prisoners coupled with
the major adverse biological and social factors associated
with severe drug dependence [43], suggests that very
powerful interventions to assist smoking cessation will be
required to increase quit rates in this population.Limitations
One limitation of this study is that heroin use was
assessed by participant self-report, so may not reflect the
true proportion of prisoners who had ever or recently
used heroin. Some prisoners may have been concerned
about admitting to an illegal behaviour while in prison.
However, the use of independent research nurses was
expected to improve the confidence of participants that
their responses would be kept confidential. This study
was also limited by only including males so cannot ne-
cessarily be generalised for female prisoners. Also, this
study was also limited by its stringent inclusion and ex-
clusion criteria, which were necessary in ensuring safe
administration of nortriptyline, but which excluded a high
proportion of men interested in quitting smoking. It is not
possible to determine if the men who were eligible were
more or less likely to use heroin than those who were not
so the generalisability of these findings must be considered
with caution. Another limitation of the study is that partici-
pants were not asked if they were on an opioid substitution
program or if they were currently using heroin so we can-
not determine if this had an impact on smoking cessation
success. Despite these limitations, this study has a number
of strengths including: a strong follow-up rate of 80% at
12 months; recruitment across nearly all male prisons in
NSW; adherence to a rigorous study protocol; and utilising
a tailored multi-component smoking cessation interven-
tion that was piloted among prisoners [3].
Conclusions
The key finding of this study was that, before entering
prison, prisoners who had regularly used heroin were
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than prisoners who did not report regular heroin use.
This suggests that smoking cessation interventions for
prisoners should take into account prisoners’ recent drug
(particularly heroin) use in order to develop an effective
intervention which tackles both smoking and illicit drug
use. More research may assist in determining if these inter-
ventions should occur as a combined model or separately
and the optimal timing of their implementation.
Many prisoners wish to quit smoking. Incarceration
presents an opportune time to attempt engaging pris-
oners in smoking cessation interventions. More research
is needed to determine how best to support prisoners
who regularly used heroin to quit smoking. Some evi-
dence suggests that when people are able to quit smok-
ing, they are better able to stop using illicit drugs, which
may result in reductions in re-offending, as well as sig-
nificant improvements in health and well-being.
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